Management of Adverse Pathology after Radical Prostatectomy

Posted by Jason A. Efstathiou, MD, DPhil | Jun 2019

Jason A. Efstathiou, MD, MPhil, presented “Management of Adverse Pathology after Radical Prostatectomy” during the 24th Annual Southwest Prostate Cancer Symposium on April 12, 2019 in Scottsdale, Arizona.

How to cite: Efstathiou, Jason A. “Management of Adverse Pathology after Radical Prostatectomy” April 12, 2019. Accessed Apr 2024. https://grandroundsinurology.com/external-beam-radiation-therapy-for-high-risk-locally-advanced-prostate-cancer-the-shifting-landscape/

Management of Adverse Pathology after Radical Prostatectomy – Summary:

Jason A. Efstathiou, MD, DPhil, reviews the results of randomized studies and large retrospective experiences evaluating the efficacy, safety, and timing of post-prostatectomy radiation. He discusses the role of androgen deprivation therapy in addition to radiation in the salvage postoperative setting, and the potential use of genomic and advanced imaging biomarkers in patient treatment selection.

About the Southwest Prostate Cancer Symposium

The Southwest Prostate Cancer Symposium (SPCS) is a multi-day conference that seeks to educate urologists, radiation oncologists, medical oncologists, and other healthcare professionals involved in the treatment of prostate cancer. The topics focus on current technical aspects of diagnosis and treatment of localized and advanced disease, particularly regarding imaging, technology, and training in the related devices. Dr. Efstathiou presented this lecture during the 24th SPCS in 2019. In 2020, the 25th SPCS will also offer training sessions involving imaging, scanning, and prostate cancer treatment-related devices on site. Please visit this page in order to register for future SPCS meetings.

About The Author

Jason A. Efstathiou, MD, DPhil

Jason A. Efstathiou, MD, DPhil, is Professor of Radiation Oncology at Harvard Medical School (HMS) as well as Director of the Genitourinary (GU) Division in the Department of Radiation Oncology and Clinical Co-Director of the Claire and John Bertucci Center for GU Cancers at Massachusetts General Hospital. He is a recognized leader in the fields of GU malignancies and radiation oncology. His research has informed clinical guidelines and made novel contributions to innovations such as organ preservation therapy for bladder cancer, technology assessment of proton beam therapy for prostate cancer, indications for and adverse effects of androgen deprivation therapy for prostate cancer, improving radiation therapy for testicular cancer, and global oncology outreach efforts. He holds leadership positions within cooperative groups (NRG), professional societies (ASTRO), and the NCI. Dr. Efstathiou holds a BS from Yale University, his MD from HMS, and a DPhil from the University of Oxford, and completed his residency training through the Harvard Radiation Oncology Program.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat